Afghanistan

Population 2018 37 million

<table>
<thead>
<tr>
<th>Estimates of TB burdenº, 2018</th>
<th>Number (thousands)</th>
<th>Rate per 100 000 population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>70 (45–100)</td>
<td>189 (122–270)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.32 (0.12–0.64)</td>
<td>0.87 (0.31–1.7)</td>
</tr>
<tr>
<td>MDR-RR-TB incidenceºº</td>
<td>2.5 (1–4.7)</td>
<td>6.8 (2.8–13)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>11 (6.4–16)</td>
<td>29 (17–44)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.098 (0.036–0.19)</td>
<td>0.26 (0.1–0.52)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases 3% (1.4–5.3)
- Previously treated cases 12% (11–14)

TB case notifications, 2018

Total new and relapse 48 420
- % tested with rapid diagnostics at time of diagnosis 24%
- % with known HIV status 53%
- % pulmonary 71%
- % bacteriologically confirmedººº 64%
- % children aged 0-14 years 21%
- % women 46%
- % men 33%

Total cases notified 48 800

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018 69% (48–110)
- TB patients facing catastrophic total costs 16% (8–26)

TB/HIV care in new and relapse TB patients, 2018

Number (%)
- Patients with known HIV status who are HIV-positive 7 <1%
- on antiretroviral therapy 3 43%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ººº
- New cases 49%
- Previously treated cases 95%

Laboratory-confirmed cases* MDR/RR-TB: 452, XDR-TB: 8

Patients started on treatment* ** MDR/RR-TB: 319, XDR-TB: 8

MDR/RR-TB cases tested for resistance to second-line drugs 253

Treatment success rate and cohort size

Success Cohort
New and relapse cases registered in 2017 91% 46 640
Previously treated cases, excluding relapse, registered in 2017 42% 766
HIV-positive TB cases registered in 2017 29% 7
MDR-RRTB cases started on second-line treatment in 2016 82% 153
XDR-TB cases started on second-line treatment in 2016

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment 95% (88–100)
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2019

National TB budget (US$ millions) 17

Funding source: 3% domestic, 76% international, 21% unfunded

º Ranges represent uncertainty intervals
ºº MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-03-11 Data: www.who.int/tb/data